1、 赵榆华,傅宴,雷婷,等. 替格瑞洛联合比伐卢定对STEMI急诊PCI无复流临床研究[J]. 现代医院, 2014, 14(8):30-32. 赵榆华,傅宴,雷婷,等. 替格瑞洛联合比伐卢定对STEMI急诊PCI无复流临床研究[J]. 现代医院, 2014, 14(8):30-32.
2、 STONE GW, WITZENBICHLER B, WEISZ G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drugeluting stents (ADAPT-DES): a prospective multicentre registry study[J]. Lancet, 2013, 382(9): 614-623. STONE GW, WITZENBICHLER B, WEISZ G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drugeluting stents (ADAPT-DES): a prospective multicentre registry study[J]. Lancet, 2013, 382(9): 614-623.
3、 SIMON T, VERSTUYFT C, MARY-KRAUSE M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl JMed, 2009, 360(4): 363-375. SIMON T, VERSTUYFT C, MARY-KRAUSE M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl JMed, 2009, 360(4): 363-375.
4、 TRENK D, STONE GW, GAWAZ M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high plateletreactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study [J]. J Am Coll Cardiol, 2012, 59(24): 2159-2164. TRENK D, STONE GW, GAWAZ M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high plateletreactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study [J]. J Am Coll Cardiol, 2012, 59(24): 2159-2164.
5、 SCOTT SA,SANGKUHL K,GARDNER EE,et al. Clinical pharmacogenetic simplementation consortium guidelines for cytochrome P450-2C19( CYP2C19) genotype and clopidogrel therapy[J]. Clinical Pharmacology and Therapeutics, 2011, 90(5): 328-331. SCOTT SA,SANGKUHL K,GARDNER EE,et al. Clinical pharmacogenetic simplementation consortium guidelines for cytochrome P450-2C19( CYP2C19) genotype and clopidogrel therapy[J]. Clinical Pharmacology and Therapeutics, 2011, 90(5): 328-331.
6、 FRELINGER AL, BHATT DL, LEE RD, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1,PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function[J]. J Am Coll Cardiol, 2013, 61(8): 872-879. FRELINGER AL, BHATT DL, LEE RD, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1,PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function[J]. J Am Coll Cardiol, 2013, 61(8): 872-879.
7、 李建华,曹剑,范利. 氯吡格雷抵抗临床防治的研究进展[J]. 中华老年心脑血管病杂志,2015, 17(12):1324-1326. 李建华,曹剑,范利. 氯吡格雷抵抗临床防治的研究进展[J]. 中华老年心脑血管病杂志,2015, 17(12):1324-1326.
8、 ANTMAN EM, HAND M, ARMSTRONG PW, et al. 2007 Focused Update of the ACC /AHA 2004 Guidelines for the Management of Patients With ST.Elevation Myocardial Infarction:A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines:Developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians:2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Writing on Behalf of the 2004 Writing Committee[J]. Circulation, 2008,1 17(5):296-329. ANTMAN EM, HAND M, ARMSTRONG PW, et al. 2007 Focused Update of the ACC /AHA 2004 Guidelines for the Management of Patients With ST.Elevation Myocardial Infarction:A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines:Developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians:2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Writing on Behalf of the 2004 Writing Committee[J]. Circulation, 2008,1 17(5):296-329.
9、 ANDERSON JL, ADAMS CD, ANTMAN EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the AmericanCollege of Cardiology/American Heart Association Task Force on Practice Guidelines(Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians,the Society for Cardiovascular Angiography and Interventions,and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine[J]. Circulation, 2012, 126(7):875-876. ANDERSON JL, ADAMS CD, ANTMAN EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the AmericanCollege of Cardiology/American Heart Association Task Force on Practice Guidelines(Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians,the Society for Cardiovascular Angiography and Interventions,and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine[J]. Circulation, 2012, 126(7):875-876.
10、 PRIYADHARSINI R,SHEWADE DG,SUBRAJA K,et al. Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population[J]. Mol Biol Rep,2014,41(10):7265-7271. PRIYADHARSINI R,SHEWADE DG,SUBRAJA K,et al. Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population[J]. Mol Biol Rep,2014,41(10):7265-7271.
11、 SAMOS M, SIMONOVA R, KOVIR F, et al. Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis[J]. Am J Emerg Med, 2014, 32 (3): 461-465. SAMOS M, SIMONOVA R, KOVIR F, et al. Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis[J]. Am J Emerg Med, 2014, 32 (3): 461-465.
12、 AL-AZZAM SI, ALZOUBI KH, KHABOUR OF, et al. Factors that contribute to clopidogrel resistance in cardiovascular disease patients:environmental and genetic approach[J]. Int J Clin Pharmacol Ther,2013,51(6):179-186. AL-AZZAM SI, ALZOUBI KH, KHABOUR OF, et al. Factors that contribute to clopidogrel resistance in cardiovascular disease patients:environmental and genetic approach[J]. Int J Clin Pharmacol Ther,2013,51(6):179-186.
13、 GAO W,ZHANG Q,GE H,et al. Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation[J]. Angiology,2013,64(9):554-558. GAO W,ZHANG Q,GE H,et al. Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation[J]. Angiology,2013,64(9):554-558.
14、 陈希伟,吴同果,韦建瑞,等. 复方丹参滴丸对氯吡格雷抵抗患者血小板聚集功能影响的研究[J]. 广州医药, 2012, 43(2): 26-29. 陈希伟,吴同果,韦建瑞,等. 复方丹参滴丸对氯吡格雷抵抗患者血小板聚集功能影响的研究[J]. 广州医药, 2012, 43(2): 26-29.
15、 WAND S,BARO D,BAECKER C,et al. Response to dual antiplatelet therapy in patients with peripheral artery occlusive diseasesuffering from critical limb ischemia[J]. Clin Lab,2014,60(8):1601-1607. WAND S,BARO D,BAECKER C,et al. Response to dual antiplatelet therapy in patients with peripheral artery occlusive diseasesuffering from critical limb ischemia[J]. Clin Lab,2014,60(8):1601-1607.
16、 SZAPARY L,KOLTAI K,TIBOLD A,et al. Clopidogrel resistance in cerebrovascular disease-results of one-year follow-up[J]. Orv Hetil,2015,156(10):53-59. SZAPARY L,KOLTAI K,TIBOLD A,et al. Clopidogrel resistance in cerebrovascular disease-results of one-year follow-up[J]. Orv Hetil,2015,156(10):53-59.
